InflaRx N.V.(IFRX) - 2024 Q4 - Annual Report

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones Jena, Germany, March 20, 2025 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the year ended December 31, 2024, highlighting recent operational achievements and expected milestones for 2025. Exhibit 99.1 Vilobelimab in PG – Pivotal Phase 3 trial interim analysis expected by the end of ...